Motixafortide alone and in combination with natalizumab (VLA-4 inhibitor) led to robust hematopoietic stem cell (HSC) ...

Cambridge-based Fulcrum Therapeutics said it will aim to launch a large clinical trial in the second half of 2026 to prove ...

About 100,000 people in the U.S. have sickle cell disease, a condition that primarily affects people of color, the CDC says.

Less than a third of ED visits for acute sickle cell disease pain were guideline-adherent for the timely administration of ...

A study assessing the real-world commercial roll-out of gene therapies for sickle cell disease and beta thalassemia offers ...

Cellarity, a clinical-stage biotechnology company developing Cell State-Correcting therapies through integrated multi-omics and AI modeling, today announced the presentation of new preclinical data on ...

Only 1 in 3 patients in an ER for sickle cell crisis receive opioid painkillers within the first hour as treatment guidelines ...

Adding erythropoietin to hydroxyurea treatment could significantly improve quality of life for patients with sickle cell ...

Key Highlights Motixafortide effectively mobilized sufficient hematopoietic stem cells (HSCs) in patients with sickle cell disease enabling accelerated access to gene therapies 90% (9 of 10) of ...

The first study assessing the real-world commercial roll-out of gene therapies for sickle cell disease and beta thalassemia ...

Preliminary results from two trials of the gene therapy exagamglogene autotemcel (exa-cel) suggest the therapy offers an ...